Disulfiram/Cu Kills and Sensitizes BRAF-Mutant Thyroid Cancer Cells to BRAF Kinase Inhibitor by ROS-Dependently Relieving Feedback Activation of MAPK/ERK and PI3K/AKT Pathways

BRAF(V600E), the most common genetic alteration, has become a major therapeutic target in thyroid cancer. Vemurafenib (PLX4032), a specific inhibitor of BRAF(V600E) kinase, exhibits antitumor activity in patients with BRAF(V600E)-mutated thyroid cancer. However, the clinical benefit of PLX4032 is of...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Jingyi, Liu, Juan, Zhao, Man, Li, Xinru, Wang, Yubo, Zhao, Yuelei, Cao, Hongxin, Ji, Meiju, Chen, Mingwei, Hou, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968072/
https://www.ncbi.nlm.nih.gov/pubmed/36834830
http://dx.doi.org/10.3390/ijms24043418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968072/
https://www.ncbi.nlm.nih.gov/pubmed/36834830
http://dx.doi.org/10.3390/ijms24043418

Ejemplares similares